News

The company has submitted a new drug application (NDA) under the FDA’s fast track program and is based on results from the PARADIGM-HF trial, which is claimed to

Kerasal Complete Care brings together two highly effective treatments to restore healthy nail appearance and treat toe and foot skin fungus (athlete’s foot) in a convenient dual-pack. Moberg

The drug is indicated to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ALO-02 is an extended-release

Simultaneously, the company has requested the FDA for fast track designation for Actimmune. The company also intends to commence a Phase III trial in the second quarter of

As part of the deal, Lonza will manufacture material for the Phase III trial of Cx601 in the US at Lonza’s cell therapy production facility in Walkersville, US.

In September 2014, the company reported positive results from a Phase II trial of MOB-015. The new patent includes composition of matter claims directed to a new topical

Recently, the company started a Phase I clinical trial evaluating the combination of VS-5584 and VS-6063 to treat patients with relapsed or progressive malignant pleural mesothelioma. The combination

Under the deal, PATH will provide funding to support product development, preclinical testing and manufacturing, with the goal to qualify and select a final development candidate to advance

The multicenter, dose-escalation Phase I trial is designed to evaluate the safety and tolerability of ALRN-6924 as a single agent. ALRN-6924 is a potent and specific re-activator of